Laboratorios Rubió launches Soludronate® Semanal 70 mg. solución oral, the first and only alendronic acid oral solution for prevention and treatment of osteoporosis, mainly postmenopausal. This ready-to-take formulation facilitates administration and reduces side effects associated with other alendronic acid dosage forms, improving patient adherence to treatment.
Soludronate® Weekly presents viscosifying agents that optimize the transport through the digestive system and allow a faster access of the treatment to the place of absorption, contributing to a better gastric tolerance, favoring the compliance of the pattern marked by the specialist.
The objective of Rubió Laboratories is to make known this treatment option through a medical visit to specialists who treat patients with osteoporosis diagnosis, mainly postmenopausal.
